γδ-TCR iPS Cell Reprogramming Without Antibody Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to generate induced pluripotent stem cells (iPS cells) with rearranged γδ-TCR genes effectively, particularly for use in cancer treatment, as they often require antibody treatments that are cumbersome and limited by MHC restriction, and do not adequately expand γδT cells for sufficient therapeutic use.
Innovation Solution
A method involving stimulation of blood cells with IL-2 and a bisphosphonate, followed by introduction of cell reprogramming factors using a Sendai virus (SeV) vector, without prior antibody treatment, to generate iPS cells with rearranged γδ-TCR genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If antibody treatment is used to purify T cells with desired antigen specificity, then cell purity can be improved, but the process complexity and time required increase
Solution Approach 1:
The patent extracts and eliminates the antibody treatment step from the conventional T cell purification process. By using Sendai virus vectors to directly introduce reprogramming factors into γδT cells without prior antibody-mediated purification, the method removes a complex and time-consuming step while maintaining cell specificity through direct viral transduction of the target cell population.
Solution Approach 2:
The patent applies preliminary action by pre-stimulating blood cells with IL-2 and bisphosphonate before viral transduction. This preliminary stimulation enriches the γδT cell population and prepares cells for efficient reprogramming, eliminating the need for subsequent antibody treatment to achieve sufficient cell purity and functionality.
2Quantity of substance
If the amount of blood collected is increased to secure sufficient TST cells for treatment, then cell number can be improved, but the burden on the patient increases
Solution Approach 1:
The patent changes the stimulation parameters by using IL-2 and bisphosphonate to enhance γδT cell expansion from small blood samples. This parameter change enables sufficient cell numbers to be obtained from minimal blood collection, thereby reducing patient burden while maintaining therapeutic cell quantities.
3Quantity of substance
If γδT cells are expanded ex vivo from peripheral blood, then cell number can be improved, but expansion efficiency and activation are insufficient
Solution Approach 1:
The patent introduces Sendai virus vectors as a new parameter for delivering reprogramming factors directly to γδT cells. This enables efficient ex vivo expansion and reprogramming in a single integrated step, dramatically improving productivity compared to conventional methods that require separate purification, expansion, and reprogramming steps.
Solution Approach 2:
The patent merges the steps of cell expansion and reprogramming into a single integrated process. By combining viral transduction with IL-2 and bisphosphonate stimulation, the method simultaneously achieves cell number expansion and reprogramming, eliminating the inefficiencies of sequential operations.
4Reliability
If conventional reprogramming methods are used on T cells, then iPS cells can be generated, but MHC restriction limits therapeutic applicability
Solution Approach 1:
The patent applies local quality by focusing reprogramming on γδT cells with specific TCR gene rearrangements rather than attempting to reprogram all T cell subsets. This targeted approach preserves the unique anti-tumor specificity of γδT cells while achieving reliable reprogramming, thereby maintaining both reliability and therapeutic adaptability.
Solution Approach 2:
Instead of attempting to overcome MHC restriction by reprogramming conventional αβT cells, the patent inverts the approach by selecting γδT cells that naturally exhibit MHC-unrestricted cytotoxicity. This inversion allows the reprogramming process to work with the inherent properties of the cell type, eliminating MHC restriction limitations while maintaining reprogramming reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method efficiently generates iPS cells with rearranged γδ-TCR genes, eliminating the need for antibody treatment and enabling differentiation into γδT cells for broad cancer cell attack, thus overcoming limitations of existing technologies.
Implementation Method 1
introducing at least four kinds of genes capable of expressing cell reprogramming factors into the blood cells through use of a Sendai virus vector
Implementation Method 2
stimulating collected blood cells with any one kind or a plurality of kinds of interleukins selected from IL-2, IL-15, and IL-23, and a bisphosphonate
Data Source
AI summary
Provided is a method of generating iPS cells. Specifically, provided is a method of generating iPS cells having a rearranged γδ-TCR gene. Also provided is a cell population including the generated iPS cells. The method includes stimulating collected blood cells with IL-2 and a bisphosphonate, and then introducing cell reprogramming factors through use of a Sendai virus (SeV) vector. According to the method of the present invention, iPS cells having a rearranged γδ-TCR gene can be effectively generated. In particular, the method may be free of a step of treating the blood cells with an antibody before the step of stimulating blood cells with any one kind or a plurality of kinds of interleukins selected from IL-2, IL-15, and IL-23, and a bisphosphonate. In addition, iPS cells generated by the method of the present invention can be differentiated into desired cells by differentiation induction treatment.